secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K
Filed at:   2025-02-11T23:59:59+00:00
Accession:  0000882095-25-000003
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead Q4 revenue up 6% to $7.6B; full year EPS hit by $4.2B impairment
-----------------------------------------------------------------------

- Q4 product sales ex-Veklury +13% to $7.2B; HIV sales +16% to $5.5B, Biktarvy +21% to $3.8B.
- Full year 2024 diluted EPS $0.38 vs $4.50, reflecting $4.2B Immunomedics IPR&D impairment and $3.9B CymaBay charge.
- Non-GAAP diluted EPS Q4 $1.90 (+10%); full year $4.62 vs $6.72; cash, equivalents & securities $10.0B.
- FY2025 guidance: product sales $28.2-28.6B; non-GAAP EPS $7.70-8.10; Veklury sales expected $1.4B.
- Issued $3.5B senior notes in Q4; paid $973M dividends and repurchased $350M stock.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000088209525000003/0000882095-25-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000088209525000003/gild-20250211.htm
  HTML page:      https://secwatch.observer/filing/0000882095-25-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer